Compare Gilead Sciences, Inc. (GILD) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Iron Mountain Inc — how do they compare? Gilead Sciences, Inc. trades at $133.6 (market cap $163.51B), while Iron Mountain Inc trades at $122.95 (market cap $36.75B). The key difference: Gilead Sciences, Inc. is far larger — about 4.4× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.8%). Which is the better fit depends on your goals.
| GILD | IRM | |
|---|---|---|
Market Cap | $163.51B | $36.75B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $133.06 |
52-Week Low | $108.22 | $78.86 |
Enterprise Value | $178.05B | $55.88B |
Dividend Yield | 2.49% | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Iron Mountain (IRM) trades at $122.66, up 0.24% on the day, with a bullish analyst consensus price target of $138.67. Recent earnings beats and strong data center growth drive optimism, but high debt levels and a negative shareholder equity position pose fundamental risks. The technical picture is mixed, with moving averages bullish but oscillators bearish, and the stock is trading near key resistance at $123.
The outlook is cautiously optimistic, supported by recurring revenue streams and data center expansion, yet elevated valuation multiples and significant leverage require careful monitoring. Investment opportunity lies in execution on growth initiatives, while primary risks include interest rate sensitivity and competitive pressures in the information management sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
